Introduction: Ovulation dysfunction is one of the most common causes (prevalence 30-40%) of infertility. PCOS is one of the common cause of infertility. Letrozole is a potent, non stetoidal, aromatase inhibitor which is currently being used as ovulation inducing agent with few side effects. The aim is use of Letrozole as a first line ovulation inducing agent in polycystic ovarian syndrome (PCOS) as an alternative other commonly used ovulation induction agent. Methods: Total 220 patients of PCOS were included in the study. Diagnosis of PCOS was made on Rotterdam criteria. All patients received 2.5 mg Letrozole daily since day 2-6 of cycle. Human chorionic gonadotrophin was administered at a dose of 5,000 IU when at least 1 mature follicle (17-25mm) was detected. Timed intercourse was advised to the patients after 24-36 hrs of hCG. Then the number of follicles, endometrial thickness, ovulation rate & pregnancy rate were measured. Results: In this study 95.45% patients ovulated on first cycle, mono follicular development was significant greater in majority (86.4%) and only 2 patients developed mild OHSS, with good endometrial response, majority developed ET > 7.1mm. Out of 220 patients, 42 patients conceived out of which 14 had miscarriage, 10 had ectopic pregnancy. Conclusion:Letrozole can be used as a first line drug to induce ovulation and pregnancy in PCOS patients.

Background and Aim: Serum adiponectin levels were found to be altered in women with polycysticovary syndrome (PCOS) due to the increased adiposity commonly observed in them. Accordingly,earlier studies have reported decreased adiponectin levels in PCOS women. the present study wasconducted to measure serum adiponectin levels in women with PCOS and to evaluate its associationwith the biochemical parameters studied.Material and Methods: The present study included 50women of reproductive age attending the department of Gynecology, tertiary care institute of Indiaand diagnosed with polycystic ovary syndrome based on Rotterdam criteria. Fifty age-matchedhealthy women were recruited as controls. t. Adiponectin levels were measured along withmeasurement of fasting blood glucose, lipid profile using commercial kits and insulin resistance(HOMA-IR) was calculated. Results: Both the study groups were matched concerning age, however,PCOS women were obese when compared to healthy women (p<0.001). Serum total cholesterol andtriglyceride levels were significantly higher (p≤0.05) and serum adiponectin concentration wassignificantly lower in PCOS women when compared to controls (p≤0.05). HDL cholesterol, fastinginsulin and HOMA-IR were similar between cases and controls. Adiponectin did not show significantassociation with any of the parameters studied (Table 2). Conclusion: Serum adiponectin levels aresignificantly lower in women with polycystic ovary syndrome compared to healthy women. Thehyperandrogenemia which is one of the characteristic features of PCOS leads to a state of adipositywhich can further cause a decrease in adiponectin levels.

No abstract

No abstract